La cadena de opciones muestra datos clave de las opciones de acciones de Imunon a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Imunon..

Imunon (NASDAQ:IMNN) Bolsa, Cadena de Opciones

IMUNON INC

Imunon

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Box,Headquarters,In,Redwood,City,,California,,Usa,-,June,8,

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BROG

CETX

CODI

GLXY

IFRX

IMNN

JFBR

JOBY

LAES

LVWR

NEHC

OKTA

PMAX

SGBX

SONN

WORX

Descubre qué acciones destacan en el premercado de EE. UU., desde subidas explosivas como Box hasta caídas por anuncios clave.

Las acciones de Box se disparan un 12%; Aquí están 20 acciones que se mueven en el premercado

New,York,,Usa,-,January,07,,2025:,E2open,Website,Displayed

ABEO

BLMZ

CMBM

DGLY

DGNX

ETWO

GORV

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IXHL

ONCY

PRTA

SBET

SILO

VVPR

Consulta las acciones con mayores subidas y caídas en el premercado estadounidense de hoy, incluyendo tecnológicas, biotecnológicas y más.

Las acciones de E2open se disparan un 25%; aquí están 20 acciones que se mueven en el premercado

Imunon Inc

Press Releases

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq's Listing Requirement, Anticipates Additional Compliance Period

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

IMUNON Announces Reverse Stock Split

IMUNON Announces Stock Dividend Boosting Shareholder Value

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

Abpro Hldgs

Ainos

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Edesa Biotech

Evaxion

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

Geovax Labs

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Kairos Pharma

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Leap Therapeutics

Moleculin Biotech

Marker Therapeutics

MetaVia

Neuphoria Therapeutics Inc. - Common Stock

Neuphoria Therapeutics

NextCure

Passage Bio

Portage Biotech

SAB Biotherapeutics

Synlogic

HC Wainwright & Co.

EF Hutton

Alliance Global Partners

Comments

Imunon

Imunon (IMNN) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL